Towards a Tailored Treatment of Chronic Lymphocytic Leukemia

Dear Colleagues,

Chronic lymphocytic leukemia (CLL) is one of the most frequent types of leukemia, representing 1.1% of all cancer cases, with 18,740 new cases and 4,490 deaths for CLL in 2023 in the U.S. and an estimated 10-year prevalence of 49.8 people per 100,000 inhabitants in the UK. The modern treatment of CLL has dramatically changed thanks to the development of effective mechanism-driven drugs, which have been proven to be superior to chemoimmunotherapy, independent of age. Because the choice and management of treatment largely depend on both disease-related and patient-specific features, we set out to discuss and put into perspective (i) prognostic/predictive factors in the era of novel drugs, (ii) treatment sequencing, (iii) the monitoring of responses and resistance to treatment, (iv) the management of adverse events, and (v) innovative therapeutic options. This Special Issue will highlight the current state of the art of the tailored treatment of CLL in addition to future prospects for salvage treatment in patients refractory to BTK and BCL2 inhibitors.

Prof. Dr. Antonio Cuneo
Prof. Dr. Paolo Prospero Ghia
Prof. Dr. Francesca Romana Mauro
Dr. Marta Coscia
Prof. Dr. Gianluca Gaidano
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.